

Newsletter

Issue 15 • Nov 2024




Recruitment and study progress

This month recruitment has been steadily increasing. Up till now 1206 participants were screened and 1100 participants have been randomized— fantastic! We are making progress towards our initial target of 1,500–2,000 participants. The diagram below shows the inclusion per subgroup. In the newsletter of September 2024 we stressed the importance of enrolling dialysis patients. As you can see the recruitment in the dialysis group is catching up. The number of screen failures remains limited at 5.6%. Retention in the trial is also good, with as yet only 4.1% of randomized subjects stopping study medication early.

This newsletter offers the latest updates across each country. We greatly appreciate the continued support and contributions toward the global enrollment and retention of Renal Lifecycle participants!

Distribution over the three subgroups



■ CKD ■ Dialysis ■ Transplant

REDCap topics of the month

Units for lab values

We would like to inform you that, during routine data validation, the Sponsor Team noticed inconsistent laboratory values in REDcap. We would like to draw your attention to the **units in REDCap**. Please verify that the values and units align with the lab reports at your center. If you find that the unit used at your center is not listed, please notify the Sponsor Team.

Key Developments Across Regions

Spain

First, a warm welcome to all Spanish investigators! We are excited to announce that funding has been secured to expand the Renal Lifecycle trial to Spain. Dr. Jose Luis Górriz will serve as the national leader, with 19 centers collaborating. All centers are diligently working to gather the necessary documentation to complete the ethics submission by December 2024.



Belgium

The final start-up activities have been planned for the six participating sites in Belgium. They will start enrolling the first participants in early 2025 and are confident that these efforts will contribute to the success of the Renal Lifecycle Trial.

Australia

The Australian sites have achieved a significant milestone by randomizing 150 participants in the Renal Lifecycle trial. Additionally, we welcome John Hunter Hospital as the 16th participating site. Together, they are working on reaching the target of 250 Australian participants!

The Netherlands

The Dutch sites have successfully recruited 665 participants – excellent work! The first participant of the trial reached last week the 2 year visit! We kindly encourage all sites to keep on enrolling participants to help us reach the target of 1500-2000 participants. Many thanks for your continued efforts!

Germany

Finally, we would like to extend our compliments to the German sites for successfully reaching their target of enrolling 250 participants in 2024. They have done an excellent job and also maintain high participant retention, and some sites (our compliments to Tuebingen and the Charité, Berlin) are still actively enrolling new participants.



www.renal-lifecycle.com



renal.lifecycle.trial@umcg.nl